Pharmacovigilance & Risk Management, Inc. PVRM Home
PVRM Services
Clinical & Regulatory Services
Risk Asssessment & Management
Procedures & Training
About Sidney Kahn

About Sidney Kahn

Dr. Sidney Kahn has been at the forefront of recent US and international developments in pharmacovigilance, risk assessment, and risk management for the past decade. He holds a medical degree from the University of Cape Town, South Africa, a Ph.D. from the University of London, and specialist certification in Chemical Pathology (Clinical Biochemistry) by the Royal College of Pathologists, London. He is also a member of the Faculty of Pharmaceutical Medicine of the Royal College of Physicians, U.K. After 17 years in academic laboratory medicine in the UK and USA directing large hospital laboratories and conducting basic research in clinical biochemistry and neuroimmunology, he joined the pharmaceutical industry in 1990 and began working on safety assessment of medicinal products throughout their life cycle.

In addition to his quotidian pharmacovigilance responsibilities, Dr. Kahn has been an active participant in US and international pharmacovigilance groups, including:

  • Chairing the Terminology Subcommittee of the PhRMA Committee on Clinical Safety
  • Representing PhRMA on the ICH M1 Expert Working Group on Medical Terminology, which developed MedDRA
  • Representing PhRMA on the MedDRA MSSO evaluation panel
  • Representing PhRMA on the MedDRA Term Selection Points To Consider working group
  • Representing PhRMA on the ICH V1 EWG established in February 2002
  • Representing PhRMA on the National Coordinating Council for Medication Error Reporting and Prevention
  • Membership of the Leadership Team of the PhRMA Safety, Epidemiology & Post-Marketing Surveillance Technical Group

Dr. Kahn is currently a member of the CIOMS VI working group on clinical trial safety assessment and the DIA GCDM Terminology Management SIAC.

In his most recent industry position as Executive Director, Global Pharmacovigilance and Labeling, Bristol-Myers Squibb Company, he managed a large group of physicians and scientists responsible for the safety assessment of investigational and marketed products and personally developed innovative approaches to signal detection and evaluation and risk management plans for developmental and newly marketed products.

Dr. Kahn has given many presentations on various aspects of pharmacovigilance, including:

  • Implementation and application of MedDRA from medical, operational, and regulatory perspectives
  • Optimization of safety labeling
  • The implications of evolving regulatory and other international developments for the safety functions of pharmaceutical companies

Pharmacovigilance & Risk Management, Inc.
401 Crescent Road
Wyncote, PA 19095
Office: +1 215 885 0212
Mobile: 215.266.0608
Fax: +1 215 885 0213